Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12071MR)

This product GTTS-WQ12071MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12071MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13700MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ12583MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ7251MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ15135MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ14346MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ14974MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ3225MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ12538MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW